Saint Louis University Conducting Study to Evaluate the Safety and Immunogenicity of a West Nile Virus
03/06/2025
The purpose of this study is to evaluate the safety and immunogenicity of the HydroVax-001B WNV vaccine in healthy adult participants. This study addresses the urgent need for a vaccine to prevent WNV disease.
There is currently no licensed human vaccine for WNV, and prior vaccine approaches showed limited ability to induce a robust immune response. This study is significant to public health as it seeks to develop a vaccine that can protect both healthy and vulnerable populations from severe disease and death due to WNV infection.
Study Information
- You will be in this study for about 13 months.
- All participants will receive 3 doses of study product.
- You will be compensated for completed visits.
- You must be between 18-49 years old.
Please contact the nurse to schedule an appointment.
Saint Louis University
Center for Vaccine Development
314-977-6333
vaccine@slu.edu